Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study
Pavel, M.E.; Baudin, E.; Öberg, K.E.; Hainsworth, J.D.; Voi, M.; Rouyrre, N.; Peeters, M.; Gross, D.J.; Yao, J.C.
Annals of Oncology Official Journal of the European Society for Medical Oncology 30(12): 2010
2019
ISSN/ISBN: 1569-8041
PMID: 31406974
DOI: 10.1093/annonc/mdz222
Accession: 069237573
PDF emailed within 0-6 h: $19.90
Related References
Pavel, M.E.; Baudin, E.; Öberg, K.E.; Hainsworth, J.D.; Voi, M.; Rouyrre, N.; Peeters, M.; Gross, D.J.; Yao, J.C. 2017: Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study Annals of Oncology: Official Journal of the European Society for Medical Oncology 28(7): 1569-1575Pavel, M.E.; Baudin, E.; Öberg, K.E.; Hainsworth, J.D.; Voi, M.; Rouyrre, N.; Peeters, M.; Gross, D.J.; Yao, J.C. 2019: Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study Annals of Oncology: Official Journal of the European Society for Medical Oncology 30(12): 2010
Fahey, T.J. 2012: Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study Yearbook of Surgery 2012: 184-186
Pavel, M.E.; Hainsworth, J.D.; Baudin, E.; Peeters, M.; Hörsch, D.; Winkler, R.E.; Klimovsky, J.; Lebwohl, D.; Jehl, V.; Wolin, E.M.; Öberg, K.; Van Cutsem, E.; Yao, J.C. 2011: Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study Lancet 378(9808): 2005-2012
Fazio, N.; Granberg, D.; Grossman, A.; Saletan, S.; Klimovsky, J.; Panneerselvam, A.; Wolin, E.M. 2013: Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors: analysis of the phase 3, randomized, placebo-controlled RADIANT-2 study Chest 143(4): 955-962
Pavel, M.; Singh, N.; Passos, V.; Oberg, K. 2011: Poster Impact of Prior Somatostatin Analog (Ssa) Use on Pfs in the Multicenter, Phase Iii Trial of Everolimus + Octreotide Lar Vs Placebo + Octreotide Lar in Patients With Advanced Neuroendocrine Tumours (Radiant-2) European Journal of Cancer 47: S462-S463
Yao, J.; Fazio, N.; Singh, S.; Buzzoni, R.; Carnaghi, C.; Wolin, E.; Tomasek, J.; Raderer, M.; Lahner, H.; Voi, M.; Pacaud, L.; Lincy, J.; Sachs, C.; Valle, J.; Delle Fave, G. 2015: 5Lba Everolimus in advanced nonfunctional neuroendocrine tumors (Net) of lung or gastrointestinal (Gi) origin: Efficacy and safety results from the placebo-controlled, double-blind, multicenter, Phase 3 Radiant-4 study European Journal of Cancer 51: S709-S710
Pavel, M.E.; Becerra, C.; Grosch, K.; Cheung, W.; Hasskarl, J.; Yao, J.C. 2017: Effect of everolimus on the pharmacokinetics of octreotide long-acting repeatable in patients with advanced neuroendocrine tumors: An analysis of the randomized phase IIi RADIANT-2 trial Clinical Pharmacology and Therapeutics 101(4): 462-468
Yao, J.C.; Fazio, N.; Singh, S.; Buzzoni, R.; Carnaghi, C.; Wolin, E.; Tomasek, J.; Raderer, M.; Lahner, H.; Voi, M.; Pacaud, L.B.; Rouyrre, N.; Sachs, C.; Valle, J.W.; Fave, G.D.; Van Cutsem, E.; Tesselaar, M.; Shimada, Y.; Oh, D.-Y.; Strosberg, J.; Kulke, M.H.; Pavel, M.E. 2016: Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study Lancet 387(10022): 968-977
Yao, J.C.; Pavel, M.; Lombard-Bohas, C.; Van Cutsem, E.; Voi, M.; Brandt, U.; He, W.; Chen, D.; Capdevila, J.; de Vries, E.G.E.; Tomassetti, P.; Hobday, T.; Pommier, R.; Öberg, K. 2016: Everolimus for the Treatment of Advanced Pancreatic Neuroendocrine Tumors: Overall Survival and Circulating Biomarkers from the Randomized, Phase IIi RADIANT-3 Study Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 34(32): 3906-3913
Pavel, M.E.; Singh, S.; Strosberg, J.R.; Bubuteishvili-Pacaud, L.; Degtyarev, E.; Neary, M.P.; Carnaghi, C.; Tomasek, J.; Wolin, E.; Raderer, M.; Lahner, H.; Valle, J.W.; Pommier, R.; Van Cutsem, E.; Tesselaar, M.E.T.; Fave, G.D.; Buzzoni, R.; Hunger, M.; Eriksson, J.; Cella, D.; Ricci, J.-F.ço.; Fazio, N.; Kulke, M.H.; Yao, J.C. 2017: Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial LANCET. Oncology 18(10): 1411-1422
Fazio, N.; Carnaghi, C.; Buzzoni, R.; Valle, J.W.; Herbst, F.; Ridolfi, A.; Strosberg, J.; Kulke, M.H.; Pavel, M.E.; Yao, J.C. 2021: Relationship between metabolic toxicity and efficacy of everolimus in patients with neuroendocrine tumors: a pooled analysis from the randomized, phase 3 RADIANT-3 and RADIANT-4 trials Cancer 127(15): 2674-2682
Jonathan Chambers; Nick Reed; Was Mansoor; Paul Ross; Ashley Grossman 2010: Phase-3 randomized trial of everolimus (RAD001) vs. placebo in advanced pancreatic NET (RADIANT-3) Regulatory Peptides 164(1): 6-7
Yao, J.C.; Phan, A.T.; Chang, D.Z.; Wolff, R.A.; Hess, K.; Gupta, S.; Jacobs, C.; Mares, J.E.; Landgraf, A.N.; Rashid, A.; Meric-Bernstam, F. 2008: Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase Ii study Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 26(26): 4311-4318
Culp, S.H.; Wood, C.G. 2009: Words of wisdom. Re: Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomized, placebo- controlled phase IIi trial European Urology 55(6): 1484-1485
Lombard-Bohas, C.; Yao, J.C.; Hobday, T.; Van Cutsem, E.; Wolin, E.M.; Panneerselvam, A.; Stergiopoulos, S.; Shah, M.H.; Capdevila, J.; Pommier, R. 2015: Impact of prior chemotherapy use on the efficacy of everolimus in patients with advanced pancreatic neuroendocrine tumors: a subgroup analysis of the phase IIi RADIANT-3 trial Pancreas 44(2): 181-189
Rinke, A.; Wittenberg, M.; Schade-Brittinger, C.; Aminossadati, B.; Ronicke, E.; Gress, T.M.; Müller, H.-H.; Arnold, R. 2017: Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients with Metastatic Neuroendocrine Midgut Tumors (PROMID): Results of Long-Term Survival Neuroendocrinology 104(1): 26-32
Castellano, D.; Bajetta, E.; Panneerselvam, A.; Saletan, S.; Kocha, W.; O'Dorisio, T.; Anthony, L.B.; Hobday, T. 2013: Everolimus plus octreotide long-acting repeatable in patients with colorectal neuroendocrine tumors: a subgroup analysis of the phase IIi RADIANT-2 study Oncologist 18(1): 46-53
Zhao, H.; Fan, Y.; Ma, S.; Song, X.; Han, B.; Cheng, Y.; Huang, C.; Yang, S.; Liu, X.; Liu, Y.; Lu, S.; Wang, J.; Zhang, S.; Zhou, C.; Wang, M.; Zhang, L. 2015: Final overall survival results from a phase III, randomized, placebo-controlled, parallel-group study of gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804) Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer 10(4): 655-664
Strosberg, J.R.; Yao, J.C.; Bajetta, E.; Aout, M.; Bakker, B.; Hainsworth, J.D.; Ruszniewski, P.B.; Van Cutsem, E.; Öberg, K.; Pavel, M.E. 2015: Efficacy of octreotide long-acting repeatable in neuroendocrine tumors: RADIANT-2 placebo arm post hoc analysis Endocrine-Related Cancer 22(6): 933-940